Publications

Detailed Information

Ki-67 Expression Gives Additional Prognostic Information on St. Gallen 2007 and Adjuvant! Online Risk Categories in Early Breast Cancer

DC Field Value Language
dc.contributor.authorJung, So-Youn-
dc.contributor.authorHan, Wonshik-
dc.contributor.authorLee, Jong Won-
dc.contributor.authorKo, Eunyoung-
dc.contributor.authorKim, Eunkyu-
dc.contributor.authorYu, Jong-Han-
dc.contributor.authorMoon, Hyeong-Gon-
dc.contributor.authorPark, In Ae-
dc.contributor.authorOh, Do-Youn-
dc.contributor.authorIm, Seock-Ah-
dc.contributor.authorKim, Tae-You-
dc.contributor.authorHwang, Ki-Tae-
dc.contributor.authorKim, Sung-Won-
dc.contributor.authorNoh, Dong-Young-
dc.date.accessioned2012-05-24T07:31:15Z-
dc.date.available2012-05-24T07:31:15Z-
dc.date.created2021-01-12-
dc.date.created2021-01-12-
dc.date.created2021-01-12-
dc.date.issued2009-05-
dc.identifier.citationAnnals of Surgical Oncology, Vol.16 No.5, pp.1112-1121-
dc.identifier.issn1068-9265-
dc.identifier.other120637-
dc.identifier.urihttps://hdl.handle.net/10371/76442-
dc.description.abstractWe sought to determine the significance of Ki-67, one of the tumor cell proliferation markers, as a useful prognostic factor in early breast cancer. A total of 1080 consecutive patients with stage I or II breast cancer that underwent surgery between 1998 and 2003 were enrolled. Patients were categorized on the basis of the 2007 St. Gallen consensus and Adjuvant! Online. The expression of Ki-67 in the tumor was assayed by immunohistochemistry (cutoff value, 10%). Univariate analysis determined that tumor size, lymph node involvement, histologic grade, estrogen receptor, progesterone receptor, bcl-2, and Ki-67 (a parts per thousand yen10%) were statistically significant for both overall survival (OS) and distant metastasis-free survival (DFS). Of these factors, lymph node involvement and high Ki-67 expression were identified as independent prognostic factors for OS and DFS on the basis of multivariate analysis. The survivals of intermediate- and high-risk groups according to 2007 St. Gallen consensus were further separated by Ki-67 expression level (5-year DFS rate = 91.9% vs. 86.3% for Ki-67 < 10% and a parts per thousand yen10%, respectively in intermediate-risk group (P = .01); 5-year DFS rate = 82.5% vs. 61.4% for Ki-67 < 10% and a parts per thousand yen10%, respectively in high-risk group (P = .01)). The survivals of low- and high-risk groups according to Adjuvant! Online were further separated by Ki-67 expression level (5-year DFS rate = 97.8% vs. 89.5% for Ki-67 < 10% and a parts per thousand yen10%, respectively in low-risk group (P = .02); 5-year DFS rate = 9.4% vs. 82.6% for Ki-67 < 10% and a parts per thousand yen10% in high-risk group (P = .005)). Ki-67 is an independent prognostic factor for DFS and OS in early breast cancer and can provide additional prognostic information on the risk stratification with the use of the 2007 St. Gallen consensus and Adjuvant! Online.-
dc.language영어-
dc.language.isoenko_KR
dc.publisherLippincott Williams & Wilkins Ltd.-
dc.titleKi-67 Expression Gives Additional Prognostic Information on St. Gallen 2007 and Adjuvant! Online Risk Categories in Early Breast Cancer-
dc.typeArticle-
dc.contributor.AlternativeAuthor임석아-
dc.identifier.doi10.1245/s10434-009-0334-7-
dc.citation.journaltitleAnnals of Surgical Oncology-
dc.description.citedreferenceHarris L, 2007, J CLIN ONCOL, V25, P5287, DOI 10.1200/JCO.2007.14.2364-
dc.description.citedreferenceGoldhirsch A, 2007, ANN ONCOL, V18, P1133, DOI 10.1093/annonc/mdm271-
dc.description.citedreferenceAhn SH, 2007, J CLIN ONCOL, V25, P2360, DOI 10.1200/JCO.2006.10.3754-
dc.description.citedreferencede Azambuja E, 2007, BRIT J CANCER, V96, P1504, DOI 10.1038/sj.bjc.6603756-
dc.description.citedreferenceDowsett M, 2007, J NATL CANCER I, V99, P167, DOI 10.1093/jnci/djk020-
dc.description.citedreferenceRailo M, 2007, TUMOR BIOL, V28, P45, DOI 10.1159/000097702-
dc.description.citedreferenceBuyse M, 2006, J NATL CANCER I, V98, P1183, DOI 10.1093/jnci/djj329-
dc.description.citedreferenceColozza M, 2005, ANN ONCOL, V16, P1723, DOI 10.1093/annonc/mdi352-
dc.description.citedreferenceAbe O, 2005, LANCET, V365, P1687-
dc.description.citedreferenceOlivotto IA, 2005, J CLIN ONCOL, V23, P2716, DOI 10.1200/JCO.2005.06.178-
dc.description.citedreferenceWang YX, 2005, LANCET, V365, P671-
dc.description.citedreferenceJacquemier J, 2005, CANCER RES, V65, P767-
dc.description.citedreferenceErdem O, 2005, TUMORI, V91, P46-
dc.description.citedreferencePaik S, 2004, NEW ENGL J MED, V351, P2817-
dc.description.citedreferenceSun JM, 2004, CANCER, V101, P2516, DOI 10.1002/cncr.20665-
dc.description.citedreferenceCaly M, 2004, ANTICANCER RES, V24, P3283-
dc.description.citedreferenceGoldhirsch A, 2003, J CLIN ONCOL, V21, P3357, DOI 10.1200/JCO.2003.04.576-
dc.description.citedreferenceVolpi A, 2003, J CLIN ONCOL, V21, P2708, DOI 10.1200/JCO.2003.04.008-
dc.description.citedreferenceRoila F, 2003, ANN ONCOL, V14, P843, DOI 10.1093/annonc/mdg256-
dc.description.citedreferenceTrihia H, 2003, CANCER, V97, P1321-
dc.description.citedreferencevan de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999-
dc.description.citedreferencePalazzi M, 2002, TUMORI, V88, P503-
dc.description.citedreferenceBoyages J, 2002, BRIT J SURG, V89, P789-
dc.description.citedreferenceSpyratos F, 2002, CANCER, V94, P2151, DOI 10.1002/cncr.10458-
dc.description.citedreferenceBillgren AM, 2002, BREAST CANCER RES TR, V71, P161-
dc.description.citedreferenceIwamoto E, 2001, JPN J CLIN ONCOL, V31, P259-
dc.description.citedreferenceRavdin PM, 2001, J CLIN ONCOL, V19, P980-
dc.description.citedreferenceLau R, 2001, INT J ONCOL, V18, P17-
dc.description.citedreferenceRudolph P, 1999, J NATL CANCER I, V91, P271-
dc.description.citedreferenceThor AD, 1999, J CLIN ONCOL, V17, P470-
dc.description.citedreferenceMolino A, 1997, INT J CANCER, V74, P433-
dc.description.citedreferencePietilainen T, 1996, J CANCER RES CLIN, V122, P687-
dc.description.citedreferenceBrown RW, 1996, CLIN CANCER RES, V2, P585-
dc.description.citedreferenceCHER ML, 1995, PROSTATE, V26, P87-
dc.description.citedreferenceVERONESE SM, 1993, CANCER, V71, P3926-
dc.description.citedreferenceGALEA MH, 1992, BREAST CANCER RES TR, V22, P207-
dc.description.citedreferenceELSTON CW, 1991, HISTOPATHOLOGY, V19, P403-
dc.description.citedreferenceGERDES J, 1991, AM J PATHOL, V138, P867-
dc.description.citedreferenceQUIRKE P, 1986, J PATHOL, V149, P79-
dc.description.citedreferenceDEAN PN, 1984, CELL TISSUE KINET, V17, P427-
dc.description.citedreferenceMALAISE EP, 1973, EUR J CANCER, V9, P305-
dc.description.tc19-
dc.identifier.wosid000264878900009-
dc.identifier.scopusid2-s2.0-64249146434-
dc.citation.endpage1121-
dc.citation.number5-
dc.citation.startpage1112-
dc.citation.volume16-
dc.identifier.sci000264878900009-
dc.description.isOpenAccessY-
dc.contributor.affiliatedAuthorHan, Wonshik-
dc.contributor.affiliatedAuthorPark, In Ae-
dc.contributor.affiliatedAuthorOh, Do-Youn-
dc.contributor.affiliatedAuthorIm, Seock-Ah-
dc.contributor.affiliatedAuthorKim, Tae-You-
dc.contributor.affiliatedAuthorKim, Sung-Won-
dc.contributor.affiliatedAuthorNoh, Dong-Young-
dc.type.docTypeArticle-
dc.description.journalClass1-
dc.subject.keywordPlusINTERNATIONAL EXPERT CONSENSUS-
dc.subject.keywordPlusCELL-PROLIFERATION-
dc.subject.keywordPlusMONOCLONAL-ANTIBODY-
dc.subject.keywordPlusCLINICAL-PRACTICE-
dc.subject.keywordPlusPRIMARY THERAPY-
dc.subject.keywordPlusPHASE FRACTION-
dc.subject.keywordPlusMITOTIC INDEX-
dc.subject.keywordPlusMARKERS-
dc.subject.keywordPlusVALIDATION-
dc.subject.keywordPlusSURVIVAL-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share